---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005554"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T18:10:50.916501+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q4 revenue down 10% YoY; FY2023 guidance flat to +2%

## Summary
- Q4 2022 net revenue $115.5M (-10% YoY); net income $7.5M vs $51.0M in Q4 2021.
- FY2022 net revenue $450.9M (-4% YoY); net income $15.5M vs $94.2M in FY2021.
- FY2023 guidance: revenue $450-462M (flat to +2%); net income $7.2-13.9M.
- PuraPly revenue expected to decline 18-26% in FY2023 to $180-200M.
- Adjusted EBITDA FY2023 guidance $36.5-46.0M vs $49.3M in FY2022.

## SEC filing metadata
- accession: 0000950170-23-005554
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000095017023005554/0000950170-23-005554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000095017023005554/orgo-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005554
- JSON: https://secwatch.observer/filing/0000950170-23-005554.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005554.txt

## Key facts
- Earnings Releases
  Organogenesis Holdings Inc. reported the fourth quarter ended December 31, 2022 results: revenue $115.5 million, net income $7.5 million, EPS $0.06 per share. Guidance initiated.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $115.5 million
  - Net income: $7.5 million
  - EPS: $0.06 per share
  - Guidance: initiated
  - Result: reported results
  source text: Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2022. Fourth Quarter 2022 Financial Results Summary: • Net revenue of $115.5 million for the fourth quarter of 2022, a decrease of 10% compared to net revenue of $127.9 million for the fourth quarter of 2021. Net revenue for the fourth quarter of 2022 consists
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661181/000095017023005554/0000950170-23-005554-index.htm
- Earnings Releases
  Organogenesis Holdings Inc. reported the year ended December 31, 2022 results: revenue $450.9 million, net income $15.5 million. Guidance initiated.
  - Period: the year ended December 31, 2022
  - Revenue: $450.9 million
  - Net income: $15.5 million
  - Guidance: initiated
  - Result: reported results
  source text: of 2022, compared to Adjusted EBITDA of $26.3 million for the fourth quarter of 2021, a decrease of $12.3 million. Fiscal Year 2022 Financial Results Summary: • Net revenue of $450.9 million for the year ended December 31, 2022, a decrease of 4% compared to net revenue of $467.4 million for the year ended December 31, 2021. Net revenue for the year ended December 31,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661181/000095017023005554/0000950170-23-005554-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.